Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Factor VIII exposure, bleeding outcomes, and inhibitor development in 80 previously untreated patients and minimally treated patients with severe hemophilia A on emicizumab prophylaxis : real-world data from the PedNet Registry

de Kovel, Marloes ; Kenet, Gili ; Motwani, Jayashree ; Andersson, Nadine G. LU ; Blatný, Jan ; Castaman, G. ; Carcao, Manuel ; Ettingshausen, C. Escuriola ; Königs, C. and Male, C. , et al. (2026) In Journal of Thrombosis and Haemostasis
Abstract

Background Subcutaneous emicizumab prophylaxis is increasingly used for early prophylaxis in infants with severe hemophilia A (SHA). Although the HAVEN 7 trial (NCT04431726) reported on 55 infants with SHA, real-world information regarding factor (F)VIII exposure, inhibitor development, and bleeding on this age group remains limited. Objectives To describe FVIII exposure, model-based annualized bleeding rate, and FVIII inhibitor development in infants with SHA starting emicizumab prophylaxis as previously untreated patients (PUPs) or minimally treated patients (MTPs; 1-5 FVIII-exposure days). Methods Data on PUPs and MTPs with SHA on emicizumab for ≥12 weeks were extracted from the prospective, observational multicenter PedNet Registry... (More)

Background Subcutaneous emicizumab prophylaxis is increasingly used for early prophylaxis in infants with severe hemophilia A (SHA). Although the HAVEN 7 trial (NCT04431726) reported on 55 infants with SHA, real-world information regarding factor (F)VIII exposure, inhibitor development, and bleeding on this age group remains limited. Objectives To describe FVIII exposure, model-based annualized bleeding rate, and FVIII inhibitor development in infants with SHA starting emicizumab prophylaxis as previously untreated patients (PUPs) or minimally treated patients (MTPs; 1-5 FVIII-exposure days). Methods Data on PUPs and MTPs with SHA on emicizumab for ≥12 weeks were extracted from the prospective, observational multicenter PedNet Registry on January 1, 2025, Participants in HAVEN 7 were excluded. FVIII exposure and inhibitor development were determined by survival analysis. Written informed consent was obtained from all parents/guardians. Results This study included 80 infants (39 PUPs) starting emicizumab at a median of 8.6 months followed for a median of 19.5 months. During follow-up, 47/80 (59%) infants received FVIII for bleeding or concomitant prophylaxis ( n = 10), with delayed first exposure at median 5.0 (MTPs) and 21.2 months (PUPs), respectively. The mean annualized bleeding rate was 0.6/year (95% CI, 0.4-1.1). Five infants (2 PUPs) developed FVIII inhibitors after 4 to 18 EDs, a cumulative incidence of 35.2% (95% CI, 8.6-61.7). No serious adverse events or thrombosis were reported. Conclusion These data show delayed FVIII exposure and good bleeding control without adverse events. Preliminary analysis suggested no decrease in FVIII inhibitor development. PedNet will continue to collect data needed to reliably assess the influence of different FVIII exposure during emicizumab prophylaxis on FVIII inhibitor development in PUPs.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
contributor
Alvarèz Román, M. T. ; LU ; LU orcid and Mathews, N.
author collaboration
organization
publishing date
type
Contribution to journal
publication status
epub
subject
keywords
antibodies, neutralizing, emicizumab, factor VIII, hemophilia A, inhibitor, previously untreated patients (PUPs), registries
in
Journal of Thrombosis and Haemostasis
publisher
Elsevier
external identifiers
  • pmid:42448013
  • scopus:105047085600
ISSN
1538-7933
DOI
10.1016/j.jtha.2026.06.041
language
English
LU publication?
yes
additional info
Publisher Copyright: © 2026 International Society on Thrombosis and Haemostasis.
id
c97396da-03d0-4db5-8e06-da8c9d914605
date added to LUP
2026-10-01 23:01:31
date last changed
2026-10-02 07:31:46
@article{c97396da-03d0-4db5-8e06-da8c9d914605,
  abstract     = {{<p>Background Subcutaneous emicizumab prophylaxis is increasingly used for early prophylaxis in infants with severe hemophilia A (SHA). Although the HAVEN 7 trial (NCT04431726) reported on 55 infants with SHA, real-world information regarding factor (F)VIII exposure, inhibitor development, and bleeding on this age group remains limited. Objectives To describe FVIII exposure, model-based annualized bleeding rate, and FVIII inhibitor development in infants with SHA starting emicizumab prophylaxis as previously untreated patients (PUPs) or minimally treated patients (MTPs; 1-5 FVIII-exposure days). Methods Data on PUPs and MTPs with SHA on emicizumab for ≥12 weeks were extracted from the prospective, observational multicenter PedNet Registry on January 1, 2025, Participants in HAVEN 7 were excluded. FVIII exposure and inhibitor development were determined by survival analysis. Written informed consent was obtained from all parents/guardians. Results This study included 80 infants (39 PUPs) starting emicizumab at a median of 8.6 months followed for a median of 19.5 months. During follow-up, 47/80 (59%) infants received FVIII for bleeding or concomitant prophylaxis ( n = 10), with delayed first exposure at median 5.0 (MTPs) and 21.2 months (PUPs), respectively. The mean annualized bleeding rate was 0.6/year (95% CI, 0.4-1.1). Five infants (2 PUPs) developed FVIII inhibitors after 4 to 18 EDs, a cumulative incidence of 35.2% (95% CI, 8.6-61.7). No serious adverse events or thrombosis were reported. Conclusion These data show delayed FVIII exposure and good bleeding control without adverse events. Preliminary analysis suggested no decrease in FVIII inhibitor development. PedNet will continue to collect data needed to reliably assess the influence of different FVIII exposure during emicizumab prophylaxis on FVIII inhibitor development in PUPs.</p>}},
  author       = {{de Kovel, Marloes and Kenet, Gili and Motwani, Jayashree and Andersson, Nadine G. and Blatný, Jan and Castaman, G. and Carcao, Manuel and Ettingshausen, C. Escuriola and Königs, C. and Male, C. and Nolan, Beatrice and Olivieri, M. and Oudot, Caroline and Pergantou, H. and Ranta, Susanna and Zápotocká, E. and Fischer, Kathelijn}},
  issn         = {{1538-7933}},
  keywords     = {{antibodies, neutralizing; emicizumab; factor VIII; hemophilia A; inhibitor; previously untreated patients (PUPs); registries}},
  language     = {{eng}},
  publisher    = {{Elsevier}},
  series       = {{Journal of Thrombosis and Haemostasis}},
  title        = {{Factor VIII exposure, bleeding outcomes, and inhibitor development in 80 previously untreated patients and minimally treated patients with severe hemophilia A on emicizumab prophylaxis : real-world data from the PedNet Registry}},
  url          = {{http://dx.doi.org/10.1016/j.jtha.2026.06.041}},
  doi          = {{10.1016/j.jtha.2026.06.041}},
  year         = {{2026}},
}